1. Home
  2. NPKI vs URGN Comparison

NPKI vs URGN Comparison

Compare NPKI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NPKI
  • URGN
  • Stock Information
  • Founded
  • NPKI 1932
  • URGN 2004
  • Country
  • NPKI United States
  • URGN United States
  • Employees
  • NPKI N/A
  • URGN N/A
  • Industry
  • NPKI Metal Fabrications
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • NPKI Industrials
  • URGN Health Care
  • Exchange
  • NPKI Nasdaq
  • URGN Nasdaq
  • Market Cap
  • NPKI 459.3M
  • URGN 465.9M
  • IPO Year
  • NPKI N/A
  • URGN 2017
  • Fundamental
  • Price
  • NPKI $5.76
  • URGN $9.67
  • Analyst Decision
  • NPKI Strong Buy
  • URGN Strong Buy
  • Analyst Count
  • NPKI 1
  • URGN 7
  • Target Price
  • NPKI $12.00
  • URGN $37.21
  • AVG Volume (30 Days)
  • NPKI 711.8K
  • URGN 499.1K
  • Earning Date
  • NPKI 05-01-2025
  • URGN 05-12-2025
  • Dividend Yield
  • NPKI N/A
  • URGN N/A
  • EPS Growth
  • NPKI N/A
  • URGN N/A
  • EPS
  • NPKI N/A
  • URGN N/A
  • Revenue
  • NPKI $217,489,000.00
  • URGN $90,398,000.00
  • Revenue This Year
  • NPKI $11.74
  • URGN $38.65
  • Revenue Next Year
  • NPKI $9.67
  • URGN $118.69
  • P/E Ratio
  • NPKI N/A
  • URGN N/A
  • Revenue Growth
  • NPKI 4.74
  • URGN 9.29
  • 52 Week Low
  • NPKI $4.76
  • URGN $8.94
  • 52 Week High
  • NPKI $8.65
  • URGN $20.70
  • Technical
  • Relative Strength Index (RSI)
  • NPKI N/A
  • URGN 41.45
  • Support Level
  • NPKI N/A
  • URGN $8.94
  • Resistance Level
  • NPKI N/A
  • URGN $10.83
  • Average True Range (ATR)
  • NPKI 0.00
  • URGN 0.79
  • MACD
  • NPKI 0.00
  • URGN -0.07
  • Stochastic Oscillator
  • NPKI 0.00
  • URGN 29.67

About NPKI NPK International Inc. Common Stock

NPK International Inc Formerly Newpark Resources Inc is a diversified supplier providing environmentally-sensitive products, as well as rentals and services to customers across multiple industries. The company has two operating segments: Industrial Solutions and Fluids Systems. Fluids Systems segment which generates the majority of the revenue, provides drilling, completion, and stimulation fluids products and related technical services to customers for oil, natural gas, and geothermal projects. Geographically, the company derives majority of its revenue from the United States and also has its presence in Canada, EMEA, Latin America, and Asia Pacific regions.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: